Ariad Pharmaceuticals (NASDAQ:ARIA) and Exelixis (NASDAQ:EXEL) have both stumbled, with bad news causing significant drops in share price over the past year (Ariad has lost over 60% of its value, while Exelixis is down 30% over the last year and over 60% from its 52-week high at the beginning of 2014).
Ariad had issues with its drug Iclusig, which was pulled from the market by the FDA due to safety issues, and has now returned with stronger warning labels and a reduced market potential. Investors were hoping that Exelixis' Cometriq, which is currently approved for thyroid cancer, would be so effective in a prostate cancer trial that the trial would be stopped early. That didn't happen.
With both stocks down badly from their 52-week highs, which is the better bad news buy?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson tell you which, and why.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Will Intel Corp. Sink or Swim?
The chip giant is trading at historical highs, but it might still deserve an even richer valuation.
Don't Bother With Energy Transfer Partners LP: Enterprise Products Partners L.P. Is the Better Bet for Income Seekers
If you’re looking for income security, only one of these MLPs can deliver.
Here's Why FirstEnergy Corp.'s Stock Is Soaring Today
The utility secures a transformation investment.